Bcworld Pharm. Co., Ltd.

Hearan Suh

Seung Ki Kim

Junhee Lee

Jong Sun Lee

Sang Kyu Nam

Taekun An

Juhuen Choi

Choongho Ryu

Gughwan An

Myungkwan Chun

Jeong Ku

Hyunmi Seo

Youngdai Seo

Jisung Lim

A method for preparing an imatinib base includes reacting 4-(4-methyl-piperazinomethyl)-benzoic acid with a 2,2'-dibenzothiazolyl disulfide derivative in the presence of a phosphine derivative to prepare a novel thioester compound and preparing an imatinib base using the thioester compound as a reaction intermediate. With the method, imatinib base in higher yield and/or purity can be prepared cost-effectively.

Method for producing imatinib base

This invention relates to oral pharmaceutical compositions of metformin and rosuvastatin. In detail, a pharmaceutical composition comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia.

Pharmaceutical composition comprising metformin and rosuvastatin

The present invention relates to a novel method for preparing an imatinib base, and more particularly to a method for preparing an imatinib base, which comprises reacting 4-(4-methyl-piperazinomethyl)-benzoic acid with a 2,2'-dibenzothiazolyl disulfide derivative in the presence of a phosphine derivative to prepare a novel thioester compound and preparing an imatinib base using the thioester compound as a reaction intermediate. In addition, the invention provides a novel thioester compound, which is used in the preparation of imatinib base, and a preparation method thereof. Ultimately, the invention provides a method of preparing the imatinib base in an economic manner and in high yield and purity and is expected to be used in the commercial production of large amounts of the imatinib base.

Growing community of inventors

Seoul, South Korea

Hearan Suh